Cargando…
2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022
BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677360/ http://dx.doi.org/10.1093/ofid/ofad500.2076 |
_version_ | 1785150111337152512 |
---|---|
author | Bulens, Sandra N Hall, Amanda Jacob, Jesse T Smith, Gillian Wilson, Lucy E Vaeth, Elisabeth Wilson, Christopher Muleta, Daniel Dumyati, Ghinwa Tsay, Rebecca Maloney, Meghan Stabach, Nicole Lynfield, Ruth O’Malley, Sean Pierce, Rebecca Hertzel, Heather Czaja, Christopher A Johnston, Helen Grass, Julian E Brandenburg, Joshua Guh, Alice Magill, Shelley |
author_facet | Bulens, Sandra N Hall, Amanda Jacob, Jesse T Smith, Gillian Wilson, Lucy E Vaeth, Elisabeth Wilson, Christopher Muleta, Daniel Dumyati, Ghinwa Tsay, Rebecca Maloney, Meghan Stabach, Nicole Lynfield, Ruth O’Malley, Sean Pierce, Rebecca Hertzel, Heather Czaja, Christopher A Johnston, Helen Grass, Julian E Brandenburg, Joshua Guh, Alice Magill, Shelley |
author_sort | Bulens, Sandra N |
collection | PubMed |
description | BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s Emerging Infections Program (EIP) population-based CRAB surveillance in 9 U.S. sites. [Figure: see text] Methods: In 2020–22, among surveillance-area residents, an incident CRAB case was defined as the 1(st) isolation of A. baumannii complex resistant to ≥1 carbapenem (excluding ertapenem) from a normally sterile site or urine (or lower respiratory tract or wound, as of 2021) in a 30-day period. We included cases that underwent chart review. Cases with a culture collected ≥3 days after hospitalization were considered hospital-onset (HO); all others were community-onset (CO). Cases with a SC2+ test ≤14 days before the incident CRAB culture were compared to other CRAB cases. RESULTS: Of 406 CRAB cases representing 344 patients, 26 (6%) cases in 24 patients were SC2+. SC2+ case-patients were more likely to be female than other CRAB case-patients (58% vs 34%, p=0.02); there were no significant differences in race/ethnicity or age distribution. SC2+ cases were more likely to be obese (42% vs. 23%, p=0.03), have bacteremia (23% vs. 10%, p=0.05), and to have died (39% vs. 16%, p=0.003). SC2+ cases were also more likely to require hospitalization (100% vs. 75%, p=0.005) and have HO CRAB (58% vs 29%, p=0.003). Median hospital length of stay was longer in SC2+ cases (19 days, interquartile range [IQR] 8–30) than in other CRAB cases (14 days, IQR 7–26, p=0.42), but there were no significant differences in the percentages with intensive care unit stays or mechanical ventilation in the 7 days before CRAB culture. Culture sources and infection types in SC2+ cases vs. other CRAB cases are shown in the Table. CONCLUSION: A small minority of CRAB patients were infected with SC2+ in the 14 days before CRAB infection but these patients had epidemiological and clinical features that were distinct from other CRAB patients, including higher mortality. Infection control and clinical measures are needed to protect SC2+ patients from secondary bacterial infection and mitigate poor outcomes in those with SC2 and CRAB infection. DISCLOSURES: Ghinwa Dumyati, MD, Pfizer: Grant/Research Support Rebecca Tsay, MPH, CDC: Grant/Research Support |
format | Online Article Text |
id | pubmed-10677360 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106773602023-11-27 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 Bulens, Sandra N Hall, Amanda Jacob, Jesse T Smith, Gillian Wilson, Lucy E Vaeth, Elisabeth Wilson, Christopher Muleta, Daniel Dumyati, Ghinwa Tsay, Rebecca Maloney, Meghan Stabach, Nicole Lynfield, Ruth O’Malley, Sean Pierce, Rebecca Hertzel, Heather Czaja, Christopher A Johnston, Helen Grass, Julian E Brandenburg, Joshua Guh, Alice Magill, Shelley Open Forum Infect Dis Abstract BACKGROUND: Reports have shown increases in carbapenem-resistant Acinetobacter baumannii complex (CRAB) infections during the COVID-19 pandemic. To describe the effect of SARS-CoV-2 (SC2) infection on CRAB infection epidemiology, we analyzed data from the Centers for Disease Control and Prevention’s Emerging Infections Program (EIP) population-based CRAB surveillance in 9 U.S. sites. [Figure: see text] Methods: In 2020–22, among surveillance-area residents, an incident CRAB case was defined as the 1(st) isolation of A. baumannii complex resistant to ≥1 carbapenem (excluding ertapenem) from a normally sterile site or urine (or lower respiratory tract or wound, as of 2021) in a 30-day period. We included cases that underwent chart review. Cases with a culture collected ≥3 days after hospitalization were considered hospital-onset (HO); all others were community-onset (CO). Cases with a SC2+ test ≤14 days before the incident CRAB culture were compared to other CRAB cases. RESULTS: Of 406 CRAB cases representing 344 patients, 26 (6%) cases in 24 patients were SC2+. SC2+ case-patients were more likely to be female than other CRAB case-patients (58% vs 34%, p=0.02); there were no significant differences in race/ethnicity or age distribution. SC2+ cases were more likely to be obese (42% vs. 23%, p=0.03), have bacteremia (23% vs. 10%, p=0.05), and to have died (39% vs. 16%, p=0.003). SC2+ cases were also more likely to require hospitalization (100% vs. 75%, p=0.005) and have HO CRAB (58% vs 29%, p=0.003). Median hospital length of stay was longer in SC2+ cases (19 days, interquartile range [IQR] 8–30) than in other CRAB cases (14 days, IQR 7–26, p=0.42), but there were no significant differences in the percentages with intensive care unit stays or mechanical ventilation in the 7 days before CRAB culture. Culture sources and infection types in SC2+ cases vs. other CRAB cases are shown in the Table. CONCLUSION: A small minority of CRAB patients were infected with SC2+ in the 14 days before CRAB infection but these patients had epidemiological and clinical features that were distinct from other CRAB patients, including higher mortality. Infection control and clinical measures are needed to protect SC2+ patients from secondary bacterial infection and mitigate poor outcomes in those with SC2 and CRAB infection. DISCLOSURES: Ghinwa Dumyati, MD, Pfizer: Grant/Research Support Rebecca Tsay, MPH, CDC: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10677360/ http://dx.doi.org/10.1093/ofid/ofad500.2076 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Bulens, Sandra N Hall, Amanda Jacob, Jesse T Smith, Gillian Wilson, Lucy E Vaeth, Elisabeth Wilson, Christopher Muleta, Daniel Dumyati, Ghinwa Tsay, Rebecca Maloney, Meghan Stabach, Nicole Lynfield, Ruth O’Malley, Sean Pierce, Rebecca Hertzel, Heather Czaja, Christopher A Johnston, Helen Grass, Julian E Brandenburg, Joshua Guh, Alice Magill, Shelley 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title | 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title_full | 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title_fullStr | 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title_full_unstemmed | 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title_short | 2458. Carbapenem-resistant Acinetobacter baumannii complex infections and SARS-CoV-2 positivity in 9 U.S. sites, 2020-2022 |
title_sort | 2458. carbapenem-resistant acinetobacter baumannii complex infections and sars-cov-2 positivity in 9 u.s. sites, 2020-2022 |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677360/ http://dx.doi.org/10.1093/ofid/ofad500.2076 |
work_keys_str_mv | AT bulenssandran 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT hallamanda 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT jacobjesset 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT smithgillian 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT wilsonlucye 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT vaethelisabeth 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT wilsonchristopher 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT muletadaniel 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT dumyatighinwa 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT tsayrebecca 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT maloneymeghan 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT stabachnicole 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT lynfieldruth 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT omalleysean 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT piercerebecca 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT hertzelheather 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT czajachristophera 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT johnstonhelen 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT grassjuliane 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT brandenburgjoshua 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT guhalice 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 AT magillshelley 2458carbapenemresistantacinetobacterbaumanniicomplexinfectionsandsarscov2positivityin9ussites20202022 |